Explore

Scottish Rite for Children Introduces New ACL Reconstruction Technique for Young Athletes

Scottish Rite for Children Introduces New ACL Reconstruction Technique for Young Athletes

Scottish Rite for Children's pediatric orthopedic surgeon, Dr. Javier Masquijo, is introducing a rectus femoris ACL reconstruction technique to adolescent patients in the United States. This method, previously used in adult populations in Europe and South America, offers a new graft option specifically designed for young athletes. Traditionally, ACL reconstruction involves using tissue from hamstrings, patellar tendon, quadriceps, or iliotibial band. The rectus femoris technique utilizes the most superficial part of the quadriceps, aiming to preserve other crucial knee structures. This approach potentially reduces the impact on the graft harvest site compared to full-thickness quadriceps tendon grafts. It also preserves hamstring muscles, vital for knee stability, and may decrease anterior knee pain often associated with patellar tendon grafts. The sports medicine team at Scottish Rite is actively researching this technique, assessing functional recovery, patient-reported outcomes, and complication rates t...

Bausch + Lomb Receives European CE Mark Approval for SeeLyra Femtosecond Laser, Seeks U.S. Approval

Bausch + Lomb Receives European CE Mark Approval for SeeLyra Femtosecond Laser, Seeks U.S. Approval

Bausch + Lomb Receives European CE Mark Approval for SeeLyra Femtosecond Laser, Seeks U.S. Approval

Dr. Julie Deutsch Pioneers Biomarker Development for Personalized Cancer Treatment

Dr. Julie Deutsch Pioneers Biomarker Development for Personalized Cancer Treatment

Dr. Julie Deutsch, a physician-scientist and pathologist at Johns Hopkins University, is leading research focused on developing next-generation tissue-based biomarkers to guide cancer treatment. Her work, supported by a Cancer Research Institute (CRI) STAR award, aims to create practical biomarkers that can indicate how individual patients are responding to therapy, identify signs of response or resistance, and ultimately help clinicians match patients with the most effective treatments. Dr. Deutsch combines pathology with advanced computational approaches, including machine learning, to extract crucial information from routinely collected tissue samples. Her goal is to ensure that patients receive therapies from which they will benefit, avoiding unnecessary toxicity from ineffective treatments. She emphasizes the importance of implementing these discoveries in real-time clinical settings, making them accessible beyond major academic medical centers.

Good Medicine Podcast Highlights Challenges of Mouse Models in Drug Development

Good Medicine Podcast Highlights Challenges of Mouse Models in Drug Development

The Good Medicine Podcast, featuring Dr. David Bearss and Dr. Jeremiah Bearss, recently discussed a significant challenge in modern drug development: the limitations of mouse models. The podcast highlighted that despite drug development taking an average of 15 years and costing billions of dollars, most therapies that show promise in mouse models ultimately fail in human trials. Only a small percentage of therapies effective in mice succeed in people, leading to substantial impacts on timelines and costs within the pharmaceutical industry. The discussion emphasized the need for more predictive testing systems to improve pharmaceutical innovation and reduce the financial burden associated with failed drug candidates. The core issue is that animal models, particularly mice, often do not accurately predict human responses to drugs, leading to a high attrition rate in clinical development.

Ascension Sacred Heart Pensacola Offers Comprehensive Diabetes and Nutrition Education

Ascension Sacred Heart Pensacola Offers Comprehensive Diabetes and Nutrition Education

Ascension Sacred Heart Diabetes and Nutrition Education in Pensacola, Florida, provides comprehensive support and education for individuals living with diabetes. The center offers personalized care programs tailored to specific types of diabetes, symptoms, and related conditions such as high cholesterol, high blood pressure, and vision changes. Services include both onsite classes and virtual telehealth appointments, making education accessible to people along the Gulf Coast. The care team comprises Certified Diabetes Care and Education Specialists (CDCES), including registered nurses and dietitians, and the program is certified by the American Diabetes Association. Key educational areas cover healthy eating, active living, blood sugar monitoring, medication management, problem-solving for unexpected readings, risk reduction for long-term complications, and healthy coping strategies for managing stress. Additionally, the center provides medical nutrition therapy, which involves personalized nutrition couns...

Joaquin Duato Assumes Dual Role as Chairman and CEO of Johnson Johnson, Succeeding Alex Gorsky

Joaquin Duato Assumes Dual Role as Chairman and CEO of Johnson Johnson, Succeeding Alex Gorsky

Joaquin Duato Assumes Dual Role as Chairman and CEO of Johnson Johnson, Succeeding Alex Gorsky

Senphonix Receives National Science Foundation Grant to Advance Continuous Vitals Monitoring Platform

Senphonix Receives National Science Foundation Grant to Advance Continuous Vitals Monitoring Platform

Senphonix, Inc., a medical-technology startup, has been awarded a Small Business Technology Transfer (STTR) Phase I grant from the U.S. National Science Foundation (NSF) through America's Seed Fund. This funding will support the engineering development of SleeveSense, a wearable device designed for continuous, long-term monitoring of patients' vital signs. The award specifically targets strengthening the device's wireless and radio-frequency systems and advancing it from a prototype to a manufacturable product at scale. Senphonix is collaborating with the University of Arizona on this project, focusing on performance in real hospital environments, including antenna and power systems. The company aims to pursue U.S. Food and Drug Administration (FDA) clearance for SleeveSense in early to mid-2027, following clinical testing expected to begin in late 2026 or early 2027. This grant builds on previous support from the State of Arizona, including matching funds from the Arizona Commerce Authority.

Florida Times-Union

Nemours hearing therapy, UF Health mobile unit, new St. V's president

Nemours hearing therapy, UF Health mobile unit, new St. V's president

Nemours gets "remarkable" results in hearing therapy, while UF Health unveils a mobile unit and Ascension St. Vincent's Riverside names new president.

Partial Knee Replacement Offers Less Invasive Option for Targeted Knee Damage

Partial Knee Replacement Offers Less Invasive Option for Targeted Knee Damage

Partial knee replacement, also known as patellofemoral partial knee replacement, is a surgical procedure designed to address damage in specific areas of the knee joint, unlike total knee replacement which replaces the entire joint. This procedure is particularly suited for individuals whose arthritis or damage is confined to one compartment of the knee, such as where the kneecap meets the thighbone. The implant typically consists of a metal cap for the femur, a metal plate with a plastic spacer for the tibia, and a plastic button for the patella (kneecap). By focusing only on the damaged area, the surgery is less invasive, often involving shorter operation times and smaller incisions. This approach aims to preserve more of the natural knee structure, potentially leading to a more natural feeling of movement post-surgery. It is often considered for younger, active patients who have localized knee issues.

LUMA Vision Secures FDA Clearance for VERAFEYE Platform, Advancing Cardiac Procedural Intelligence

LUMA Vision Secures FDA Clearance for VERAFEYE Platform, Advancing Cardiac Procedural Intelligence

LUMA Vision, a medical technology company, has announced that it received FDA clearance for its VERAFEYE procedural intelligence platform. This clearance expands the platform's capabilities, moving the company closer to its goal of creating an integrated cardiac lab of the future. VERAFEYE aims to unify imaging, visualization, navigation, and guidance into a single system, providing physicians with continuous real-time visibility into the interplay of cardiac anatomy, medical devices, and therapy delivery during minimally invasive cardiac procedures. The system reconstructs 3D models of the heart's left and right atria with CT-like accuracy, allows for direct visualization and documentation of ablation delivery on the anatomy, and maintains continuous tracking of both imaging and ablation catheters through electromagnetic tracking and automated imaging. Dr. Devi Nair, Chief of Cardiac Electrophysiology & Research at St. Bernards Healthcare, highlighted the system's ability to combine real-time imaging, vis...

Leyden Labs Reports Positive Phase 1 Results for RIG-101, Advancing Asthma Protection

Leyden Labs Reports Positive Phase 1 Results for RIG-101, Advancing Asthma Protection

Leyden Laboratories B.V. (Leyden Labs) has announced positive results from a Phase 1 study of RIG-101, an investigational intranasal innate immune modulator. RIG-101 is being developed to prevent the consequences of common respiratory viral infections in vulnerable patients, particularly those with asthma. The study demonstrated that RIG-101 was safe and well-tolerated in both healthy volunteers and asthma patients across all dose levels, with up to seven days of daily administration. Biomarker analyses confirmed the activation of the intended antiviral response in the upper respiratory tract, including the induction of type I and type III interferons and interferon-stimulating genes. These findings support the advancement of RIG-101 into Phase 2 clinical development, with the next planned study being a human rhinovirus challenge study in asthma patients. RIG-101 is designed to enhance innate antiviral immune responses in patient populations with impaired natural defenses against respiratory viruses.

Autolus Therapeutics Receives FDA RMAT Designation for Obe-cel in Lupus Treatment

Autolus Therapeutics Receives FDA RMAT Designation for Obe-cel in Lupus Treatment

Autolus Therapeutics plc, a biopharmaceutical company, has announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to obecabtagene autoleucel (obe-cel). This designation is specifically for the treatment of systemic lupus erythematosus (SLE) and lupus nephritis (LN). The RMAT designation is a program established under the 21st Century Cures Act, designed to expedite the development and regulatory review process for regenerative medicine therapies, including cell therapies, that are intended to treat serious or life-threatening diseases. Autolus Therapeutics is currently enrolling patients in LUMINA, a pivotal Phase 2 study for obe-cel in refractory lupus nephritis, and expects to report data in 2028. The company also submitted a data update from the Phase 1 CARLYSLE trial for presentation at the American College of Rheumatology (ACR) Annual Meeting in the fourth quarter of 2026.